Results 51 to 60 of about 29,847 (226)

Responsive nitric oxide‐releasing antibacterial materials for biofilm‐associated infections: Mechanisms, design strategies, and applications

open access: yesResponsive Materials, EarlyView.
This review summarizes the recent progress in responsive NO‐releasing materials and their applications in biofilm‐associated infectious diseases. The design principles and response mechanisms are given to provide inspiration toward the future development of multi‐responsive NO‐releasing materials.
Wenyue Sun   +8 more
wiley   +1 more source

The sandfly vectors and epidemiology of cutaneous leishmaniasis in the Landazury Focus, Colombia. [PDF]

open access: yes
This thesis describes a comprehensive cohort study of cutaneous leishmaniasis (CL) in a population of 2,704 followed over a period of 19 months, in the Opon focus, Landazury, Santander, Colombia.
Munoz-Mantilla, Gerardo
core   +1 more source

Disseminated cutaneous leishmaniasis

open access: yesSaudi Medical Journal, 2004
Disseminated cutaneous leishmaniasis DCL is a condition rarely seen in the Middle East. We report a case of disseminated cutaneous leishmaniasis in a 60-years-old lady. The patient first presented 1996 with an initial lesion, which started on the butterfly area of the face and spread, probably due to immunosuppression, to involve the whole face.
Khalifa E, Sharquie, Rafid A, Najim
openaire   +2 more sources

Tissue Resident Memory Cells: Friend or Foe?

open access: yesImmunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude   +2 more
wiley   +1 more source

Structures, targets and recent approaches in anti-leishmanial drug discovery and development. [PDF]

open access: yes, 2011
Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002.
Karin Seifert, Seifert, Karin
core   +1 more source

Recombinant LPG3 Protein From Leishmania chagasi as an Antigen for the Diagnosis of Canine Visceral Leishmaniasis

open access: yesTropical Medicine &International Health, EarlyView.
ABSTRACT Visceral leishmaniasis (VL) is a human neglected tropical disease in which dogs participate as reservoirs of the etiological agent Leishmania chagasi. The identification of infected dogs is important to the control of VL, and recombinant proteins are strong antigen candidates for canine visceral leishmaniasis (CVL) serodiagnosis. In this work,
Thaís Viana Fialho Martins   +12 more
wiley   +1 more source

The prolonged epidemic of anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: 'bringing down the neighbourhood'. [PDF]

open access: yes, 2003
In order to investigate the distribution and causes of the spread of anthroponotic cutaneous leishmaniasis (ACL) in Kabul, Afghanistan, a cross-sectional study was conducted during 1997-98 amongst 75,787 residents in the 13 central districts of the city.
Rowland, Mark   +4 more
core   +1 more source

The Effect of Local Allergic Reaction to Intralesional Glucantime on Recovery Course of Cutaneous Leishmaniasis

open access: yesمجله دانشکده پزشکی اصفهان, 2020
Background: Systemic or intralesional injection of Glucantime in treatment of cutaneous leishmaniasis, sometimes leads to a local allergic reaction.
Saman Afkhami-Ardakani   +4 more
doaj   +1 more source

Addressing Behavioural Determinants of Cutaneous Leishmaniasis Through Community Dialogue in Kalu District, Ethiopia: A Mixed‐Methods Study

open access: yesTropical Medicine &International Health, EarlyView.
ABSTRACT Background Cutaneous leishmaniasis (CL) is a major public health challenge in Ethiopia, with 20–30,000 new cases annually. Limited awareness and misconceptions contribute to delayed care seeking, stigma, prolonged healing, and reduced uptake of preventive measures in CL‐endemic communities.
Takele Gezahegn Demie   +13 more
wiley   +1 more source

Efficacy of Thermotherapy to Treat Cutaneous Leishmaniasis Caused by Leishmania tropica in Kabul, Afghanistan: A Randomized, Controlled Trial [PDF]

open access: yes, 2005
BACKGROUND: Pentavalent antimony is the agent recommended for treatment of cutaneous leishmaniasis (CL). Its use is problematic, because it is expensive and because of the potential for drug-associated adverse effects during a lengthy and painful ...
Davies, C.R.   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy